Literature DB >> 975082

Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity.

I J Fidler, D M Gersten, M B Budmen.   

Abstract

This report describes the selection and behavior of tumor cells resistant to cytolysis by syngeneic lymphocytes. Two B16 melanoma lines, F1 (low metastasis) and F10 (high metastasis), were cultured with lymphocytes from C57BL/6 mice immunized against B16. The selection procedure involved repeated exposure of the tumor cells to lymphocytes in vitro. After each interaction, the viable tumor cells were trpsinized, replated, and designated lines F1Lr-1 and F10Lr-1. The procedure was repeated five times, yielding lines F1Lr-6 and F10Lr-6, which resisted cytolysis by syngeneic lymphocytes. Mice were given s.c. or i.v. injections of cells from lines F1, F1Lr-6, F10, or F10Lr-6. Tumor growth patterns were the same for all four lines when the cells were injected s.c., however, the incidence of pulmonary metastases differed significantly after i.v. injection. Line F10 cells yielded more pulmonary metastases than an equal number of line F1 cells (p less than 0.01). F1Lr-6 cells yielded significantly fewer metastases than an equal number of lines F1 cells (p less than 0.01). A similar difference between F10Lr-6 and F10 cells was observed. The incidence of artificial metastases after i.v. injection of F10Lr-6 cells was similar to that for F1 cells. The quantitative organ distribution, arrest, and survival of i.v.-injected tumor cells were studied by using [125]-5-iodo-2'-deoxyuridinelabeled cells. There was a significantly greater number of cells from line F10, arrested and able to survive for 14 days in lungs, than cells from line F1. In contrast, cells from either line F1Lr-6 or F10Lr-6 had a lower incidence of arrest and survival than their lymphocyte-sensitive counterparts.

Entities:  

Mesh:

Year:  1976        PMID: 975082

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  AACR centennial series: the biology of cancer metastasis: historical perspective.

Authors:  James E Talmadge; Isaiah J Fidler
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

2.  Mouse model for pre-clinical study of human cancer immunotherapy.

Authors:  Zhiya Ya; Yared Hailemichael; Willem Overwijk; Nicholas P Restifo
Journal:  Curr Protoc Immunol       Date:  2015-02-02

3.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

4.  A Flow Cytometric Assay for Investigating Melanoma Cell Adhesion to Lymphatic Endothelial Cells.

Authors:  Kristian M Hargadon; Coleman E Johnson
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.

Authors:  P De Baetselier; E Roos; L Brys; L Remels; M Gobert; D Dekegel; S Segal; M Feldman
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 6.  Steps in tumor metastasis: new concepts from intravital videomicroscopy.

Authors:  A F Chambers; I C MacDonald; E E Schmidt; S Koop; V L Morris; R Khokha; A C Groom
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

Review 7.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

8.  Field production and functional evaluation of chloroplast-derived interferon-alpha2b.

Authors:  Philip A Arlen; Regina Falconer; Sri Cherukumilli; Amy Cole; Alexander M Cole; Karen K Oishi; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2007-05-09       Impact factor: 9.803

9.  Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.

Authors:  Arthur J Liu; Shivanand Pudakalakatti; Ashvin R Jaiswal; Prasanta Dutta; Priyamvada Jayaprakash; Todd Bartkowiak; Casey R Ager; Zhi-Qiang Wang; Alexandre Reuben; Zachary A Cooper; Cristina Ivan; Zhenlin Ju; Felix Nwajei; Jing Wang; Michael A Davies; R Eric Davis; Jennifer A Wargo; Pratip K Bhattacharya; David S Hong; Michael A Curran
Journal:  Cancer Immunol Res       Date:  2020-09-11       Impact factor: 11.151

10.  N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Lora C Bailey-Downs
Journal:  Bioorg Med Chem       Date:  2013-01-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.